Revenue
No reported data
Avalyn Pharma Inc. (AVLN)
Price—Loading quote
Net income
Q1.25
Q2.25
Q1.26
Q2.26
Free cash flow
Q1.25
Q2.25
Q1.26
Q2.26
Total cash / debt
CashTotal debt
Q1.25
Q1.26
Q2.26
Financial statements
| Q2.26 | Q1.26 | Q2.25 | Q1.25 | |
|---|---|---|---|---|
| Research & development | $24.7M | $22.9M | $17.9M | $15.3M |
| Operating expenses | $31.3M | $27.9M | $21.8M | $18.7M |
| Operating income | −$31.3M | −$27.9M | −$21.8M | −$18.7M |
| Net income | −$28.9M | −$26.9M | −$20.2M | −$17.5M |
| Basic EPSper diluted share | -$0.98 | -$21.83 | -$17.63 | -$63.24 |
| Diluted EPSper diluted share | -$0.98 | -$21.83 | -$17.63 | -$63.24 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 1, 2026Form 4 | Novo Holdings A/STenPercentOwner | BuyVoting Common Stock | 555.6K | $18.00 | $10.00M | 3.88M |
| May 1, 2026Form 4 | Carroll JillDirector | BuyCommon Stock · indirect | 277.8K | $18.00 | $5.00M | 2.19M |
| May 1, 2026Form 4 | George Simeon +1TenPercentOwner | BuyCommon Stock · indirect | 277.8K | $18.00 | $5.00M | 1.12M |
| May 1, 2026Form 4 | George Simeon +1TenPercentOwner | BuyCommon Stock · indirect | 277.8K | $18.00 | $5.00M | 2.19M |